Targeted therapies: Denileukin diftitox-a step towards a 'magic bullet' for CTCL

Nature Reviews Clinical Oncology

Volumn 7, Issue 8, 2010, Pages 430-432

  Kadin, Marshall E ^a   Vonderheid, Eric C ^b  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DENILEUKIN DIFTITOX; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO;

ANTIGEN EXPRESSION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG TARGETING; FROZEN SECTION; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNE RESPONSE; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SKIN BIOPSY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DIPHTHERIA TOXIN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOMA, T-CELL, CUTANEOUS; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 77955130383     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.105     Document Type: Short Survey

References (10)

1. Manoukian, G. and Hagemeister, F. Denileukin: a novel immunotoxin. Expert Opin. Biol. Ther. 9, 1445-1451 (2009).
2. Prince, H. M. et al. Phase iii placebo-controlled trial of denileukin for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 1870-1877 (2010).
3. Olsen. e. et al. Pivotal phase iii trial of two dose levels of denileukin for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376-388 (2001).
4. Negro-vilar, A. et al. efficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: integrated analysis of three large phase iii trials [abstract]. J. Clin. Oncol. 26 (suppl.), a8551 (2008).
5. Jones, D. et al. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin. Cancer Res. 10, 5587-5594 (2004).
6. Talpur, R. et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J. Invest. Dermatol. 126, 575-583 (2006).
7. Gjerdrum, L. M. et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21, 2512-2518 (2007).
8. Duvic, M. et al. A phase iii, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 44, 940-947 (2001).
9. Dhabhar, F. s., satoskar, A. R., Bluethmann, H., David, J. R. and Mcewen, B. s. stress-induced enhancement of skin immune function: a role for gamma interferon. Proc. Natl Acad. Sci. USA 14, 2846-2851 (2000).
10. Ruter, J. et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front. Biosci. 14, 1761-1770 (2009).